These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 27289010)
1. c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer. Jin Y; Huang M; Wang Y; Yi C; Deng Y; Chen Y; Jiang L; Wang J; Shen Q; Liu R; QinghuaXi Exp Mol Pathol; 2016 Aug; 101(1):50-7. PubMed ID: 27289010 [TBL] [Abstract][Full Text] [Related]
2. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition. Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796 [TBL] [Abstract][Full Text] [Related]
3. MicroRNA-222-3p/GNAI2/AKT axis inhibits epithelial ovarian cancer cell growth and associates with good overall survival. Fu X; Li Y; Alvero A; Li J; Wu Q; Xiao Q; Peng Y; Hu Y; Li X; Yan W; Guo K; Zhou W; Wang Y; Liu J; Zhang Y; Mor G; Wen J; Yin G Oncotarget; 2016 Dec; 7(49):80633-80654. PubMed ID: 27811362 [TBL] [Abstract][Full Text] [Related]
4. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo. Zeng S; Liu S; Feng J; Gao J; Xue F Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184 [TBL] [Abstract][Full Text] [Related]
5. LncRNA MALAT1 promotes proliferation and metastasis in epithelial ovarian cancer via the PI3K-AKT pathway. Jin Y; Feng SJ; Qiu S; Shao N; Zheng JH Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3176-3184. PubMed ID: 28770968 [TBL] [Abstract][Full Text] [Related]
6. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321 [TBL] [Abstract][Full Text] [Related]
7. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608 [TBL] [Abstract][Full Text] [Related]
8. WAVE1 gene silencing via RNA interference reduces ovarian cancer cell invasion, migration and proliferation. Zhang J; Zhou S; Tang L; Shen L; Xiao L; Duan Z; Jia L; Cao Y; Mu X Gynecol Oncol; 2013 Aug; 130(2):354-61. PubMed ID: 23680521 [TBL] [Abstract][Full Text] [Related]
9. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer]. Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747 [TBL] [Abstract][Full Text] [Related]
10. HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis. Li X; Zhang NX; Ye HY; Song PP; Chang W; Chen L; Wang Z; Zhang L; Wang NN Eur Rev Med Pharmacol Sci; 2019 Jan; 23(10):4126-4135. PubMed ID: 31173282 [TBL] [Abstract][Full Text] [Related]
11. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
12. Capn4 Enhances Osteopontin Expression through Activation of the Wnt/β-Catenin Pathway to Promote Epithelial Ovarian Carcinoma Metastasis. Yang X; Sun J; Xia D; Can X; Liu L; Zhang J; Xu H; Du N; Liu W; Shen F; Zhang Z; Sun Y; Xi X Cell Physiol Biochem; 2017; 42(1):185-197. PubMed ID: 28535511 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer. Zhou S; Tang L; Wang H; Dai J; Zhang J; Shen L; Ng SW; Berkowitz RS Gynecol Oncol; 2013 Oct; 131(1):69-76. PubMed ID: 23820113 [TBL] [Abstract][Full Text] [Related]
14. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis. Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872 [TBL] [Abstract][Full Text] [Related]
15. High Expression of Cullin7 Correlates with Unfavorable Prognosis in Epithelial Ovarian Cancer Patients. Xi J; Zeng ST; Guo L; Feng J Cancer Invest; 2016; 34(3):130-6. PubMed ID: 26962950 [TBL] [Abstract][Full Text] [Related]
16. Ubiquitin-conjugating enzyme 9 promotes epithelial ovarian cancer cell proliferation in vitro. Dong M; Pang X; Xu Y; Wen F; Zhang Y Int J Mol Sci; 2013 May; 14(6):11061-71. PubMed ID: 23708104 [TBL] [Abstract][Full Text] [Related]
17. CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer. Xu JH; Wang Y; Xu D Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3225-3234. PubMed ID: 31081074 [TBL] [Abstract][Full Text] [Related]
18. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA‑320 targets mitogen‑activated protein kinase 1 to inhibit cell proliferation and invasion in epithelial ovarian cancer. Xu Y; Hu J; Zhang C; Liu Y Mol Med Rep; 2017 Dec; 16(6):8530-8536. PubMed ID: 28990044 [TBL] [Abstract][Full Text] [Related]
20. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma. Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]